— Model is predictive for human efficacy for binge eating — — BMB compound reduced binge eating in rats with a clear dose range for efficacy — — A virtual presentation discussing the findings is tentatively scheduled for Wednesday, March 10 th at 11:00AM EST — VANCOUVER, British Columbia, March 03, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG)…


Previous articleBetterLife Engages Eurofins CDMO for Next Generation Psychedelic TD-0148A Manufacturing
Next articleatai Life Sciences Announces the Closing of its $157 Million Series D Financing Round